Legal & General Group’s Stemline Therapeutics, Inc. STML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-8,927
| Closed | -$43K | – | 3540 |
|
|
2020
Q1 | $43K | Sell |
8,927
-1,545
| -15% | -$10K | ﹤0.01% | 2652 |
|
|
2019
Q4 | $111K | Buy |
10,472
+1,758
| +20% | +$17.5K | ﹤0.01% | 2565 |
|
|
2019
Q3 | $91K | Buy |
8,714
+732
| +9% | +$9.58K | ﹤0.01% | 2558 |
|
|
2019
Q2 | $122K | Buy |
7,982
+540
| +7% | +$7.81K | ﹤0.01% | 2467 |
|
|
2019
Q1 | $95K | Buy |
7,442
+2,193
| +42% | +$24.8K | ﹤0.01% | 2503 |
|
|
2018
Q4 | $50K | Buy |
5,249
+1,120
| +27% | +$14.5K | ﹤0.01% | 2697 |
|
|
2018
Q3 | $69K | Hold |
4,129
| – | – | ﹤0.01% | 2627 |
|
|
2018
Q2 | $66K | Sell |
4,129
-566
| -12% | -$10.1K | ﹤0.01% | 2631 |
|
|
2018
Q1 | $72K | Sell |
4,695
-1,200
| -20% | -$18.7K | ﹤0.01% | 2601 |
|
|
2017
Q4 | $90K | Buy |
5,895
+1,944
| +49% | +$26K | ﹤0.01% | 2634 |
|
|
2017
Q3 | $44K | Hold |
3,951
| – | – | ﹤0.01% | 2954 |
|
|
2017
Q2 | $36K | Buy |
3,951
+1,355
| +52% | +$11.3K | ﹤0.01% | 2996 |
|
|
2017
Q1 | $22K | Sell |
2,596
-347
| -12% | -$3.16K | ﹤0.01% | 3061 |
|
|
2016
Q4 | $31K | Buy |
+2,943
| New | +$35.6K | ﹤0.01% | 3018 |
|
Legal & General Group's STML Position: Q2 2020 in Review
Legal & General Group sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 8,927 shares — an estimated $43K sold.
Legal & General Group first reported a position in STML in Q4 2016 and held it in 14 quarters. The position peaked at $122K in Q2 2019. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.
- Legal & General Group reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
- Legal & General Group sold 8,927 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $43K.
- Legal & General Group first reported a position in Stemline Therapeutics, Inc. in Q4 2016 and held it in 14 quarters.
- Legal & General Group's Stemline Therapeutics, Inc. position peaked at $122K in Q2 2019.
- 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.
Based on Legal & General Group's 13F filing for Q2 2020, filed 14 Aug 2020.